Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 3, 1999
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
Background:
It may be in the interest of the CCR to continue to follow and treat certain subjects after they have completed their treatment and participation on a research protocol.
Objective:
To provide continuing treatment and medical follow-up for CCR subjects who have completed their treatment and participation on a research protocol and who are not currently entered on or eligible for another active research protocol.
Eligibility:
Subjects who have been previously enrolled on and received treatment according to an approved CCR research protocol. (clinical trial)
It is in the best...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • Subjects of any age who have been previously enrolled and treated on an approved CCR research treatment protocol.
- • It is in the best interests of the subject and the CCR for the subject to continue to receive treatment and follow-up at the NIH.
- • The subject or guardian signs the informed consent and agrees to the proposed treatment regimen.
- EXCLUSION CRITERIA:
- • Subjects who have not been previously treated on a CCR research treatment protocol.
- • Subjects who are receiving an investigational therapy.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Caryn Steakley, R.N.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials